Alzheimer’s Blood Tests Improve Diagnosis, Predict Risk Over 10 Years
Updated
Updated · The New York Times · Jul 15
Alzheimer’s Blood Tests Improve Diagnosis, Predict Risk Over 10 Years
3 articles · Updated · The New York Times · Jul 15
Summary
Research presented in London this week showed Alzheimer’s blood tests helped primary care doctors diagnose whether cognitive symptoms were caused by the disease more accurately.
A JAMA study unveiled Wednesday found the same tests could estimate a person’s risk of Alzheimer’s-related cognitive impairment over two, five and 10 years.
The tests detect amyloid and tau proteins in blood, raising hopes for easier diagnosis, earlier treatment and eventually delaying or preventing memory and thinking decline.
Experts at the Alzheimer’s Association International Conference said the results are promising, but questions remain about accuracy and how the tests should be used in practice.
A new blood test can predict your Alzheimer's risk. Is this a medical breakthrough or just a new way to worry?
We can now detect Alzheimer's plaques with a blood test. But does removing them actually stop memory loss?
FDA-Cleared Blood Tests Revolutionize Alzheimer’s Diagnosis: Early Detection, Clinical Impact, and Future Directions (2025-2026)
Overview
In 2025, the FDA cleared the first blood test for detecting amyloid plaques, marking a major breakthrough in Alzheimer's diagnosis. This test, the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, uses a simple blood draw, making diagnosis earlier, less invasive, and much more accessible for millions of Americans. By reducing patient discomfort and improving access, the new test allows for earlier intervention in the disease process. This shift promises to transform how Alzheimer's is detected and managed, offering hope for better patient outcomes and easier access to care.